Product image of Kaliumchlorid + Glucose Fresenius Kabi (Potassium Chloride, Glucose) supplied by GNH India

Kaliumchlorid + Glucose Fresenius Kabi

Active Ingredient:
Potassium Chloride, Glucose
Origin:
EU

Kaliumchlorid + Glucose Fresenius Kabi (Potassium Chloride, Glucose)

Potassium chloride, the active ingredient in Kaliumchlorid + Glucose Fresenius Kabi, is an electrolyte solution presented as an injection solution for intravenous use. It corrects hypokalemia and supplies glucose to prevent hypoglycemia during IV therapy, helping maintain plasma osmolarity and cardiac stability.

GNH India supplies Kaliumchlorid + Glucose Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Fresenius Kabi Nv/Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kaliumchlorid + Glucose is used in clinical situations that require correction of electrolyte imbalances and glucose support during intravenous therapy.

  • Hypokalemia: restores plasma potassium levels to prevent cardiac arrhythmias.
  • Electrolyte replacement therapy: supplies essential potassium ions during fluid resuscitation.
  • Prevention of hypoglycemia during IV therapy: provides glucose as an energy source to maintain plasma osmolarity.

How It Works

  • The potassium chloride component dissociates to release potassium ions, which are taken up by cells and restore extracellular potassium concentration, stabilising cardiac membrane potential. The glucose component is metabolised to generate ATP, supporting cellular energy needs and maintaining plasma osmolarity, thereby preventing hypoglycaemia during intravenous administration.

Side Effects

Adverse reactions may occur with any intravenous electrolyte solution and should be monitored.

Common Side Effects

  • Injection site pain: mild discomfort at the infusion site.
  • Phlebitis: inflammation of the vein used for administration.
  • Transient hyperkalemia: temporary rise in serum potassium.
  • Hyperglycemia: elevated blood glucose levels.

Serious or Rare Side Effects

  • Severe hyperkalemia leading to cardiac arrest.
  • Anaphylactic reaction: severe allergic response.
  • Severe hyperglycemia with ketoacidosis.
  • Cardiac arrhythmias due to rapid potassium shifts.
  • Hemolysis from improper mixing.

Precautions & Warnings

Use of Kaliumchlorid + Glucose requires careful clinical assessment and monitoring.

  • Cardiac monitoring: observe ECG for arrhythmias when correcting severe hypokalemia.
  • Renal function: assess kidney function before administration as impaired excretion can raise potassium.
  • Blood glucose: monitor glucose levels in diabetic or critically ill patients.
  • Compatibility: verify compatibility with other IV solutions to avoid precipitation.
  • Infusion rate: administer at a controlled rate to avoid rapid shifts in electrolytes.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Kaliumchlorid + Glucose can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid)

  • ACE inhibitors: may increase serum potassium, risking hyperkalemia.
  • Potassium‑sparing diuretics: additive effect on potassium levels.
  • Insulin therapy: can cause rapid intracellular potassium shift.
  • Beta‑blockers: may potentiate hyperkalemia.

Moderate Interactions (Monitor Closely)

  • Loop diuretics: increased potassium loss may require dose adjustment.
  • Sodium bicarbonate: can raise serum potassium during alkalinisation.
  • Other glucose‑containing solutions: monitor for cumulative hyperglycaemia.

Frequently Asked Questions

Kaliumchlorid + Glucose is an intravenous electrolyte solution that supplies potassium ions to correct hypokalemia and provides glucose to prevent hypoglycaemia during IV therapy. It is used in hospitals for electrolyte replacement, cardiac stability, and energy support in patients receiving parenteral nutrition or fluid resuscitation.

Potassium chloride dissociates into potassium ions after infusion. These ions increase extracellular potassium concentration, restoring normal membrane potential in cardiac and skeletal muscle cells, which helps prevent arrhythmias and supports overall cellular function.

The dose is determined by the prescribing clinician based on the patient’s serum potassium level, renal function, and overall clinical status. The healthcare professional calculates the required potassium amount and adjusts the infusion rate accordingly.

Safety data for this specific combination in pregnancy and lactation are limited. Clinicians should weigh potential benefits against risks and consider alternative therapies when possible. The decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Kaliumchlorid + Glucose combines potassium chloride with glucose, offering both electrolyte correction and an energy source in a single infusion. Standard potassium chloride injections lack glucose, so separate dextrose solutions may be required. This combination can simplify fluid management and reduce the number of IV bags needed.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required by the administration protocol.

It is administered intravenously, either as a continuous infusion or as a slow push, depending on the clinical situation. The infusion rate is set by the prescriber and monitored closely to avoid rapid changes in serum potassium or glucose levels.

The most serious risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, and severe hyperglycaemia that may lead to ketoacidosis. Anaphylactic reactions, although rare, are also a critical concern and require immediate medical attention.

Patients with known hypersensitivity to potassium chloride, glucose, or any excipients in the formulation should avoid this product. It is also contraindicated in individuals with severe renal impairment, uncontrolled hyperkalemia, or those receiving medications that significantly raise potassium levels without close monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.